Telix

Telix Launches “Gallium Wave” Awareness Website

Friday, June 11, 2021 - 1:04pm

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced the launch of a new website Gallium Wave ( galliumwave.com ), as part of the Company's gallium awareness campaign.

Key Points: 
  • Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced the launch of a new website Gallium Wave ( galliumwave.com ), as part of the Company's gallium awareness campaign.
  • The website illustrates how Telix, in partnership with suppliers, manufacturers and distributors, is paving a new path to increase future access to gallium-68 (68Ga) based radiopharmaceuticals.
  • We are excited to launch this educational resource to increase physician awareness of the reliability, flexibility and accessibility of 68Ga.
  • Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases.

Telix to Present at the 2021 Jefferies Virtual Healthcare Conference

Tuesday, June 1, 2021 - 1:00pm

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).

Key Points: 
  • Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).
  • Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States.
  • Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases.
  • For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn .

Telix and Monrol Expand Alliance to Include Lutetium Supply

Monday, May 10, 2021 - 11:56pm

Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States.

Key Points: 
  • Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States.
  • Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases.
  • For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn .\nEczac\xc4\xb1ba\xc5\x9f\xc4\xb1 Monrol Nuclear Products Co. is a leading developer, manufacturer, and distributor of radiopharmaceutical products globally.
  • Monrol exports a broad spectrum of high-quality nuclear medicine products to more than 40 countries around the world.

Telix Pharmaceuticals Appoints Mr. Richard Valeix as EMEA President

Monday, May 3, 2021 - 12:14am

b'MELBOURNE, Australia and HERSTAL, Belgium, May 02, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Mr. Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa (EMEA).\nRichard joins Telix with approximately twenty years of pharmaceutical industry experience, including radiopharmaceuticals, gained in senior executive leadership roles across a broad range of therapeutic product areas.

Key Points: 
  • b'MELBOURNE, Australia and HERSTAL, Belgium, May 02, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Mr. Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa (EMEA).\nRichard joins Telix with approximately twenty years of pharmaceutical industry experience, including radiopharmaceuticals, gained in senior executive leadership roles across a broad range of therapeutic product areas.
  • Richard brings to the Company extensive experience and a proven track record in successfully launching practice-changing radiopharmaceuticals in the diverse EMEA market.
  • Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States.
  • Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases.

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Tuesday, March 30, 2021 - 11:02pm

MELBOURNE, Australia and INDIANAPOLIS, March 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces today that it has completed an agreement with contract development and manufacturing organisation (CDMO) Grand River Aseptic Manufacturing (GRAM) to perform commercial-scale Good Manufacturing Practice (GMP) manufacturing of Telixs Illuccix product (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging.

Key Points: 
  • MELBOURNE, Australia and INDIANAPOLIS, March 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces today that it has completed an agreement with contract development and manufacturing organisation (CDMO) Grand River Aseptic Manufacturing (GRAM) to perform commercial-scale Good Manufacturing Practice (GMP) manufacturing of Telixs Illuccix product (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging.
  • Under the terms of the Agreement, GRAM will perform advanced aseptic fill and finish services for Illuccix at its facilities in Grand Rapids, (Michigan, U.S.A.) for the U.S., Canada, EU, and Australian markets.
  • GRAM President and CEO Tom Ross added, We wish to congratulate Telix on reaching this incredible milestone.
  • About Grand River Aseptic Manufacturing, Inc.
    Grand River Aseptic Manufacturing, Inc. (GRAM) , a leading parenteral contract development and manufacturing organization, delivers customized solutions to meet clients fill and finish needs from development through commercialization.

Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market

Monday, November 2, 2020 - 4:10am

Telix has appointed China Grand Pharma as its exclusive partner for the Greater China market (Territory)1 and grants China Grand Pharma exclusive development and commercialisation rights to Telixs portfolio of prostate, renal and brain (glioblastoma) cancer imaging and therapeutic MTR products in the Territory.

Key Points: 
  • Telix has appointed China Grand Pharma as its exclusive partner for the Greater China market (Territory)1 and grants China Grand Pharma exclusive development and commercialisation rights to Telixs portfolio of prostate, renal and brain (glioblastoma) cancer imaging and therapeutic MTR products in the Territory.
  • Leveraging off China Grand Pharmas capabilities and infrastructure in China, Telix will enter a significant oncology market, and by partnering with Telix, China Grand Pharma will build on its pipeline of innovative products for Greater China, as well as its strategy in Nuclear Medicine.
  • Additionally, China Grand Pharma will make a simultaneous one-time strategic equity investment of US$25M (~AU$35M) in Telix.
  • The investment is in the form of a private placement to China Grand Pharma of 20,947,181 fully paid ordinary Telix shares representing a post-issue holding by China Grand Pharma of 7.62%.

Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Thursday, September 24, 2020 - 12:00pm

Telix USA President Dr Bernard Lambert stated, We are pleased to have achieved this significant milestone with the submission of the first commercial NDA for PSMA imaging in the United States.

Key Points: 
  • Telix USA President Dr Bernard Lambert stated, We are pleased to have achieved this significant milestone with the submission of the first commercial NDA for PSMA imaging in the United States.
  • Telix has engaged with the FDA since July 2019, with valuable guidance resulting in what we believe to be a comprehensive submission.
  • Subject to FDA approval, we look forward to bringing this product to market with our commercial partners to serve the needs of men living with prostate cancer.
  • Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in prostate, kidney and brain cancer.

Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Thursday, September 24, 2020 - 12:30am

Telix USA President Dr Bernard Lambert stated, We are pleased to have achieved this significant milestone with the submission of the first commercial NDA for PSMA imaging in the United States.

Key Points: 
  • Telix USA President Dr Bernard Lambert stated, We are pleased to have achieved this significant milestone with the submission of the first commercial NDA for PSMA imaging in the United States.
  • Telix has engaged with the FDA since July 2019, with valuable guidance resulting in what we believe to be a comprehensive submission.
  • Subject to FDA approval, we look forward to bringing this product to market with our commercial partners to serve the needs of men living with prostate cancer.
  • Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in prostate, kidney and brain cancer.

Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product

Friday, May 1, 2020 - 1:14am

MELBOURNE, Australia and LIGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx (68Ga-PSMA-11 Injection) for the imaging of prostate cancer with Positron Emission Tomography (PET).

Key Points: 
  • MELBOURNE, Australia and LIGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx (68Ga-PSMA-11 Injection) for the imaging of prostate cancer with Positron Emission Tomography (PET).
  • These countries reflect the major European markets for Telixs prostate cancer imaging product.
  • In accordance with the current European Association of Urology (EAU) guidelines on prostate cancer imaging, Telix is seeking a product approval in Europe for TLX591-CDx for the indication of imaging patients with elevated prostate-specific antigen (PSA) after radical prostatectomy or radiation therapy.
  • Telix Corporate Contact Dr. Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com Telix Investor Relations Dr. David N. Cade Telix Pharmaceuticals Limited CBO and Head of Investor Relations Email: david.cade@telixpharma.com

Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer

Tuesday, October 29, 2019 - 11:00pm

APOMAB has the potential to be used for multiple cancer indications, with lung and ovarian cancers the initial focus.

Key Points: 
  • APOMAB has the potential to be used for multiple cancer indications, with lung and ovarian cancers the initial focus.
  • Telix CEO Dr. Christian Behrenbruch said, Targeted radiation has tremendous therapeutic efficacy in many different types of cancer.
  • AusHealth Managing Director and CEO Greg Johansen added, Telix is a fantastic partner for AusHealth through their contribution of their radiochemistry and commercial expertise.
  • Telix Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com Telix Investor Relations Dr. David Cade Telix Pharmaceuticals Limited CBO and Head of Investor Relations Email: david.cade@telixpharma.com